Vaccines

Parents express mixed feelings about COVID-19 vaccines, revealing a significant divide in trust and safety perceptions, according to a KFF survey analysis.

Jennifer Walsh of George Washington University’s School of Nursing warned that limiting COVID-19 vaccine approvals to older adults and high-risk groups could heighten disparities, reduce access and leave vulnerable populations at greater risk of infection and severe outcomes.

Parents are facing mixed messages on back-to-school vaccines, with David Dodd of GeoVax urging families to prioritize required school shots first, then flu and RSV, while weighing COVID-19 decisions with their pediatrician amid conflicting federal and pediatric guidance.

COVID-19 reveals significant political polarization in public health, impacting vaccine attitudes and infection concerns among Democrats and Republicans.

Experts criticize the FDA's narrow COVID-19 vaccine approval, warning it limits access and undermines public health amid rising hospitalization rates.

The FDA suspends Ixchiq, the first approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S. market.

The 2023-2024 COVID-19 vaccine proves cost-effective, especially for older adults, significantly reducing illness and hospitalizations across all age groups.

HHS reinstates the Task Force on Safer Childhood Vaccines to enhance vaccine safety and oversight amid concerns over recent ACIP changes.

Recent research confirms that aluminum in childhood vaccines does not increase the risk of autoimmune, allergic or neurodevelopmental disorders.

A new report by Commonwealth Fund ranks all 50 states and the District of Columbia across 50 indicators covering access, quality, outcomes and equity from data collected up to 2023.

The nominee for HHS secretary hedged this answers to questions about vaccine safety and efficacy at his second confirmation hearing today.

The development of avian influenza vaccines is the main priority amid rising cases in the United States.

The Biotechnology Innovation Organization has some suggestions, including "platform designation" by FDA and changes at the CDC.

A study found that the mRNA-1647 vaccine candidate developed by Moderna elicited strong immune responses. The mRNA vaccine is now in phase 3 clinical trials to determine its effectiveness in protecting against CMV.

A study published in The Lancet revealed the efficacy of a single-dose typhoid conjugate vaccine. The four-year, phase 3 trial assessed the vaccine's effectiveness in preventing typhoid fever in Malawian children.

Invivyd‘s request for EUA is supported by positive initial results from the CANOPY Phase 3 clinical trial of VYD222.

To date, two shingles vaccines have been marketed in the United States: Zostavax, approved in 2006, and Shingrix, approved in 2017. However, Zostavax is no longer available for treatment.

COVID-19 vaccines are currently administered intramuscularly. Studies indicate that intramuscular vaccine administration may not effectively generate antibodies and T cells against SARS-CoV-2 in the respiratory tract mucosa.

This study examined data from 589,722 individuals and found that those who were vaccinated had a lower incidence of long COVID compared to those who were unvaccinated.

Angela Branche, M.D., an infectious disease specialist at the University of Rochester School of Medicine, says the gaps are in a precise understanding of who is at risk for serious illness from respiratory syncytial virus and therefore who should get vaccinated.

Pfizer and BioNTech released positive top-line data for their mRNA-based combination vaccine that targets influenza and COVID-19.

Results of this prospective cohort study fits with other evidence showing no association between COVID-19 vaccination and miscarriage.